Latest Ratios: P/E Ratio 214.6x · EV/EBITDA 76.2x · ROE 2.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.4B | $9.3B | $8.1B | $10.1B | $9.7B | $15.2B | $10.3B | $4.6B | $2.4B | $1.4B | $1.1B |
| Enterprise Value | $10.5B | $9.4B | $8.0B | $10.1B | $9.6B | $14.9B | $9.9B | $4.3B | $2.3B | $1.3B | $1.0B |
| P/E Ratio → | 214.57 | 190.53 | — | 285.40 | 52.26 | 118.23 | 172.64 | 210.23 | 142.54 | 50.39 | 90.65 |
| P/S Ratio | 14.11 | 12.55 | 12.69 | 16.03 | 12.14 | 22.62 | 28.20 | 16.84 | 12.36 | 10.06 | 10.05 |
| P/B Ratio | 4.96 | 4.40 | 4.08 | 5.16 | 5.09 | 8.67 | 6.75 | 4.29 | 3.90 | 2.40 | 6.23 |
| P/FCF | 110.91 | 98.70 | 56.51 | 135.28 | 251.12 | 292.06 | 284.65 | 103.30 | 128.02 | 118.39 | 328.83 |
| P/OCF | 88.69 | 78.93 | 45.91 | 88.98 | 56.53 | 127.43 | 164.91 | 67.72 | 73.18 | 81.39 | 139.73 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.72 | 12.58 | 15.97 | 12.01 | 22.26 | 26.99 | 15.86 | 11.89 | 9.53 | 9.61 |
| EV / EBITDA | 76.18 | 67.90 | 155.12 | 75.45 | 34.18 | 72.57 | 91.23 | 70.33 | 55.26 | 55.03 | 47.14 |
| EV / EBIT | 176.88 | 109.78 | — | 170.53 | 43.70 | 90.57 | 138.55 | 120.94 | 88.80 | 98.32 | 52.27 |
| EV / FCF | — | 100.02 | 56.01 | 134.75 | 248.53 | 287.48 | 272.47 | 97.28 | 123.19 | 112.18 | 314.28 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | 53.1% | 51.1% | 55.7% | 52.5% | 54.9% |
| Operating Margin | 8.1% | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | 22.2% | 14.8% | 13.4% | 9.9% | 15.3% |
| Net Profit Margin | 6.6% | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.4% | 2.4% | -1.3% | 1.8% | 10.2% | 7.8% | 4.6% | 2.6% | 2.8% | 7.5% | 8.0% |
| ROA | 1.7% | 1.7% | -0.9% | 1.3% | 7.6% | 6.0% | 3.6% | 2.8% | 12.8% | 13.9% | 5.4% |
| ROIC | 2.2% | 2.2% | -1.4% | 1.9% | 10.1% | 9.7% | 6.5% | 4.6% | 3.7% | 3.3% | 14.0% |
| ROCE | 2.2% | 2.2% | -1.3% | 2.0% | 10.9% | 9.4% | 5.5% | 5.9% | 49.6% | 7.7% | 8.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.33 | 0.33 | 0.35 | 0.36 | 0.22 | 0.21 | 0.18 | 0.25 | 0.17 | 0.17 | 0.56 |
| Debt / EBITDA | 4.99 | 4.99 | 13.34 | 5.32 | 1.50 | 1.78 | 2.54 | 4.32 | 2.48 | 4.06 | 4.47 |
| Net Debt / Equity | — | 0.06 | -0.04 | -0.02 | -0.05 | -0.14 | -0.29 | -0.25 | -0.15 | -0.13 | -0.28 |
| Net Debt / EBITDA | 0.90 | 0.90 | -1.38 | -0.30 | -0.36 | -1.16 | -4.08 | -4.35 | -2.16 | -3.05 | -2.18 |
| Debt / FCF | — | 1.32 | -0.50 | -0.53 | -2.59 | -4.58 | -12.18 | -6.02 | -4.82 | -6.21 | -14.55 |
| Interest Coverage | 3.69 | 3.69 | -0.28 | 5.91 | 74.00 | 12.96 | 5.88 | 3.81 | 3.87 | 2.13 | 5.10 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.37 | 8.37 | 8.41 | 6.74 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 |
| Quick Ratio | 7.12 | 7.12 | 7.28 | 5.51 | 1.88 | 1.99 | 2.53 | 12.15 | 1.80 | 8.08 | 7.57 |
| Cash Ratio | 5.65 | 5.65 | 5.97 | 4.56 | 1.54 | 1.61 | 2.25 | 10.94 | 1.49 | 6.89 | 6.73 |
| Asset Turnover | — | 0.25 | 0.22 | 0.22 | 0.32 | 0.28 | 0.19 | 0.19 | 1.39 | 1.17 | 0.36 |
| Inventory Turnover | 2.29 | 2.29 | 2.52 | 1.75 | 1.45 | 1.51 | 1.81 | 2.41 | 2.03 | 1.72 | 1.91 |
| Days Sales Outstanding | — | 78.41 | 77.16 | 71.67 | 52.94 | 63.92 | 71.14 | 58.98 | 67.26 | 71.68 | 55.98 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.5% | 0.5% | — | 0.4% | 1.9% | 0.8% | 0.6% | 0.5% | 0.7% | 2.0% | 1.1% |
| FCF Yield | 0.9% | 1.0% | 1.8% | 0.7% | 0.4% | 0.3% | 0.4% | 1.0% | 0.8% | 0.8% | 0.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $56M | $56M | $57M | $57M | $54M | $49M | $45M | $39M | $34M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGEN stock.
Repligen Corporation's current P/E ratio is 214.6x. The historical average is 88.0x. This places it at the 100th percentile of its historical range.
Repligen Corporation's current EV/EBITDA is 76.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.6x.
Repligen Corporation's return on equity (ROE) is 2.4%. The historical average is -4.8%.
Based on historical data, Repligen Corporation is trading at a P/E of 214.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Repligen Corporation has 47.1% gross margin and 8.1% operating margin.
Repligen Corporation's Debt/EBITDA ratio is 5.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Margin compression persists despite growth
Metrics are mathematically derived from official filings.
Premium Pricing Implies Aggressive Recovery
With a trailing P/E of 210.6 and forward P/E of 87.5, the market is pricing in a sharp earnings rebound, as reported in recent filings, suggesting expectations of a return to historical profitability.
The current valuation multiples, including EV/EBITDA of 74.8 and P/S of 13.9, are significantly above the peer group, reflecting a premium for Repligen's pure-play exposure to bioprocessing. This premium appears to embed an assumption of a rapid recovery to 20%+ operating margins, a level not seen since before the destocking cycle. Investors should monitor whether the recent revenue acceleration translates into margin expansion to justify the multiple.
Margin Compression Masks Underlying Recovery
Gross margin improved to 53.1% in 2026Q2 from a pandemic-era low of 23.2% in 2024Q4, per quarterly filings, yet operating margin remains at 5.8%, indicating that overhead costs are still weighing on profitability.
The gap between gross and operating margins suggests that SG&A expenses, which consumed 37.5% of sales in 2026Q2, have not yet scaled down to match the new revenue base. While the gross margin recovery is encouraging, the operating margin is still far below the historical 20%+ levels, implying that the cost structure may be structurally higher. The net margin of 2.5% is further depressed by stock-based compensation and tax effects, but the cash flow statement indicates that earnings understate cash generation.
Returns on Capital Remain Subdued
ROIC of 0.4% in 2026Q2, as reported in financial statements, remains near trough levels, reflecting the impact of margin compression and a large capital base from acquisitions, though it has improved from negative levels in 2024Q4.
The return on invested capital is still far below the cost of capital, indicating that the company is not yet generating adequate returns on its acquisition-led growth. The improvement from -1.4% in 2024Q4 to 0.4% in 2026Q2 is a positive sign, but the absolute level remains low. This suggests that management's capital allocation decisions, including the $1.1B in goodwill and intangibles, have yet to yield the expected returns, and investors should monitor whether the recovery in margins can lift ROIC to double digits.
Working Capital Cycle Lengthens on Inventory
Cash conversion cycle extended to 210 days in 2026Q2, up from 169 days in 2024Q4, driven by inventory days of 174, as per recent filings, indicating that destocking is not yet complete.
The increase in DIO from 116 days in 2024Q4 to 174 days in 2026Q2 suggests that inventory levels remain elevated relative to sales, possibly reflecting anticipation of future demand or lingering excess stock. DSO has remained stable around 70 days, while DPO has increased slightly, but the overall CCC is still high, tying up cash. This inefficiency may be a temporary byproduct of the post-pandemic normalization, but it warrants monitoring as the company aims to improve working capital management.
Conservative Leverage Provides Flexibility
Debt-to-equity of 0.33 and interest coverage of 1.28 in 2026Q2, as reported in financial statements, indicate a manageable debt load, though coverage is thin relative to current earnings.
The company's leverage is modest, with total debt near $690M and a D/E ratio that has remained stable over the past ten quarters. However, the interest coverage ratio of 1.28 is low, reflecting the depressed operating income; this could become a concern if margins do not recover. The strong liquidity position, with a current ratio of 9.05 and cash of $606.8M, provides a substantial buffer, but the low coverage suggests that the company is relying on its cash pile to service debt in the near term.
Liquidity Buffer Remains Robust
Current ratio of 9.05 and quick ratio of 7.64 in 2026Q2, per recent SEC filings, indicate a strong liquidity position, with cash and equivalents providing a cushion against operational shocks.
The liquidity metrics are exceptionally strong, with the current ratio improving from 6.35 in 2024Q1 to 9.05 in 2026Q2. This suggests that the company has ample resources to fund its operations and invest in growth without immediate financing needs. However, the high inventory levels, as reflected in the quick ratio, indicate that a portion of the current assets may be less liquid, but the overall cash position mitigates this risk. The balance sheet appears well-positioned to weather continued margin pressure.
Misapplied Metric: P/E on Depressed Earnings
The trailing P/E of 210.6 is misleading given the earnings trough, as reported in financial statements, and obscures the company's cash-generative capacity, which is better captured by EV/EBITDA or P/FCF.
The P/E ratio is distorted by the current low net income, which is depressed by non-cash charges and acquisition-related costs. A more appropriate valuation metric is EV/EBITDA, which at 74.8 still appears high but better reflects the company's operating performance. Alternatively, P/FCF of 108.9 provides a clearer picture of cash generation, which has been robust relative to earnings. Investors should focus on forward multiples and cash-based metrics to assess the company's true value, as the trailing P/E may overstate the cost of the stock.